166.24 USD
+0.61 (+0.37%)
At close: Feb 11, 2026
166.24 USD
0 (0%)
After Hours: 2/11/2026, 8:00:02 PM
JAZZ gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. JAZZ has a medium profitability rating, but doesn't score so well on its financial health evaluation. JAZZ is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
- JAZZ had positive earnings in the past year.
- In the past year JAZZ had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
- Each year in the past 5 years JAZZ had a positive operating cash flow.
1.2 Ratios
- JAZZ's Return On Assets of -3.24% is fine compared to the rest of the industry. JAZZ outperforms 74.35% of its industry peers.
- The Return On Equity of JAZZ (-9.31%) is better than 75.39% of its industry peers.
- JAZZ's Return On Invested Capital of 3.95% is amongst the best of the industry. JAZZ outperforms 82.20% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 12.66%.
- The last Return On Invested Capital (3.95%) for JAZZ is above the 3 year average (3.85%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROIC | 3.95% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
- JAZZ's Profit Margin has declined in the last couple of years.
- With an excellent Operating Margin value of 10.92%, JAZZ belongs to the best of the industry, outperforming 83.25% of the companies in the same industry.
- In the last couple of years the Operating Margin of JAZZ has declined.
- The Gross Margin of JAZZ (88.49%) is better than 90.05% of its industry peers.
- In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), JAZZ is destroying value.
- Compared to 1 year ago, JAZZ has less shares outstanding
- JAZZ has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for JAZZ is higher compared to a year ago.
2.2 Solvency
- JAZZ has an Altman-Z score of 1.53. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of JAZZ (1.53) is comparable to the rest of the industry.
- JAZZ has a debt to FCF ratio of 4.33. This is a neutral value as JAZZ would need 4.33 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 4.33, JAZZ belongs to the top of the industry, outperforming 84.82% of the companies in the same industry.
- JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
- The Debt to Equity ratio of JAZZ (1.09) is worse than 73.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.53 |
ROIC/WACC0.52
WACC7.64%
2.3 Liquidity
- A Current Ratio of 1.65 indicates that JAZZ should not have too much problems paying its short term obligations.
- JAZZ has a worse Current ratio (1.65) than 68.06% of its industry peers.
- A Quick Ratio of 1.44 indicates that JAZZ should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.44, JAZZ is not doing good in the industry: 63.87% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
- JAZZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.39%.
- Measured over the past 5 years, JAZZ shows a small growth in Earnings Per Share. The EPS has been growing by 5.47% on average per year.
- JAZZ shows a small growth in Revenue. In the last year, the Revenue has grown by 4.14%.
- The Revenue has been growing by 13.48% on average over the past years. This is quite good.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
3.2 Future
- Based on estimates for the next years, JAZZ will show a small growth in Earnings Per Share. The EPS will grow by 7.67% on average per year.
- JAZZ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.06% yearly.
EPS Next Y-60.74%
EPS Next 2Y4.5%
EPS Next 3Y6.57%
EPS Next 5Y7.67%
Revenue Next Year4.8%
Revenue Next 2Y5.63%
Revenue Next 3Y6.42%
Revenue Next 5Y7.06%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 20.37, the valuation of JAZZ can be described as rather expensive.
- Based on the Price/Earnings ratio, JAZZ is valued cheaply inside the industry as 81.15% of the companies are valued more expensively.
- JAZZ's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.18.
- A Price/Forward Earnings ratio of 7.18 indicates a rather cheap valuation of JAZZ.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 93.19% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of JAZZ to the average of the S&P500 Index (28.01), we can say JAZZ is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.37 | ||
| Fwd PE | 7.18 |
4.2 Price Multiples
- JAZZ's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. JAZZ is cheaper than 87.96% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 93.72% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.15 | ||
| EV/EBITDA | 11.14 |
4.3 Compensation for Growth
- JAZZ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.73
EPS Next 2Y4.5%
EPS Next 3Y6.57%
5. Dividend
5.1 Amount
- No dividends for JAZZ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
166.24
+0.61 (+0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-03 2026-03-03/amc
Inst Owners104.02%
Inst Owner Change-2.3%
Ins Owners2.48%
Ins Owner Change-0.21%
Market Cap10.10B
Revenue(TTM)4.16B
Net Income(TTM)-368.48M
Analysts85.22
Price Target221.83 (33.44%)
Short Float %9.08%
Short Ratio4.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)1.93%
PT rev (3m)14.73%
EPS NQ rev (1m)1.33%
EPS NQ rev (3m)11.94%
EPS NY rev (1m)1.1%
EPS NY rev (3m)53.36%
Revenue NQ rev (1m)0.85%
Revenue NQ rev (3m)-0.34%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.37 | ||
| Fwd PE | 7.18 | ||
| P/S | 2.43 | ||
| P/FCF | 8.15 | ||
| P/OCF | 7.26 | ||
| P/B | 2.55 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.14 |
EPS(TTM)8.16
EY4.91%
EPS(NY)23.14
Fwd EY13.92%
FCF(TTM)20.39
FCFY12.26%
OCF(TTM)22.9
OCFY13.78%
SpS68.42
BVpS65.15
TBVpS-40.06
PEG (NY)N/A
PEG (5Y)3.73
Graham Number109.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROCE | 5% | ||
| ROIC | 3.95% | ||
| ROICexc | 5.1% | ||
| ROICexgc | 55.75% | ||
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% | ||
| FCFM | 29.8% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Debt/EBITDA | 3.8 | ||
| Cap/Depr | 22.29% | ||
| Cap/Sales | 3.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 122.16% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.53 |
F-Score5
WACC7.64%
ROIC/WACC0.52
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-60.74%
EPS Next 2Y4.5%
EPS Next 3Y6.57%
EPS Next 5Y7.67%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.8%
Revenue Next 2Y5.63%
Revenue Next 3Y6.42%
Revenue Next 5Y7.06%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-57.7%
EBIT Next 3Y5.83%
EBIT Next 5Y7.65%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.
Can you provide the valuation status for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a valuation rating of 7 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.
Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.
Can you provide the financial health for JAZZ stock?
The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.
What is the expected EPS growth for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -60.74% in the next year.